However, other studies suggest that patients with type 2 diabetes starting treatment with SGLT2 inhibitors experience a higher incidence and mortality of sepsis compared to those treated with DPP4 inhibitors (48). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.